Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Apr 26;37(6):3227–3234. doi: 10.3892/or.2017.5605

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Wang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — The expression of STAT3 and miR-1299 in tumor tissues and adjacent tissues. (A) The protein level of STAT3 and STAT3^p-Tyr705 in 60 samples of colon cancer tissues and adjacent tissues were detected with western blotting. The expression of STAT3 and STAT3^p-Tyr705 were higher in the colon cancer tissues. Data are shown as mean ± SEM. **P<0.01 vs. adjacent tissue group. (B) mRNA expression of STAT3 in 60 samples of colon cancer tissues and adjacent tissues were detected with real-time PCR. The expression of STAT3 was higher in the colon cancer tissues. Data are shown as mean ± SEM. **P<0.01 vs. adjacent tissue group. (C) Immunostaining was used to test the expression of STAT3 in 60 samples of colon cancer tissues and adjacent tissues. The expression of STAT3 was positively correlated with the TNM stage of colon cancer. (D) The levels of miR-1299 were detected by real-time PCR. There was lower expression of miR-1299 in colon cancer tissues. Data are shown as mean ± SEM. **P<0.01 vs. adjacent tissues group. (E) Survival analysis of miR-1299 and colon cancer in 60 cases of colon cancer samples. Results showed that overall survival (OS) in patients with low miR-1299 is 25.6 months, as compared with an OS of 28.4 months in patients with high level of miR-1299. P=0.0333.